Literature DB >> 17027569

A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease.

Stanley H Hsia1, Deyu Pan, Peyton Berookim, Martin L Lee.   

Abstract

Current lipid guidelines recommend that therapy be targeted primarily at low-density lipoprotein (LDL) cholesterol, and that other lipid indexes may be used as secondary or supplementary targets. Emerging data have suggested that measures such as non-high-density lipoprotein (HDL) cholesterol, apolipoprotein-B, or the total/HDL cholesterol ratio may be more predictive of cardiovascular risk than LDL cholesterol. We conducted a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey to directly compare the strengths of the associations among various lipid-related indexes and clinical features consistent with atherosclerotic disease. From approximately 9,500 data sets in the overall analysis, the apolipoprotein-B/HDL cholesterol ratio emerged as the strongest correlate (odds ratio 1.177 per 1 mg/dl increment, 95% confidence interval 1.063 to 1.302, p <0.01), followed by the total or non-HDL cholesterol/HDL cholesterol ratio (odds ratio for each 1.070 per 1 mg/dl increment, 95% confidence interval 1.024 to 1.118, p <0.01), followed by the triglyceride/HDL cholesterol ratio (odds ratio 1.033 per 1 mg/dl increment, 95% confidence interval 1.011 to 1.056, p <0.01). Neither LDL cholesterol nor the LDL/HDL cholesterol ratio correlated significantly. Parallel analyses comparing tertile extremes and analyses in subgroups determined by gender, age, and body mass index revealed similar findings. The LDL/HDL cholesterol ratio was only significant for lean patients. In conclusion, these observations add to the published data suggesting that LDL cholesterol may not be the best target of lipid-lowering treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027569     DOI: 10.1016/j.amjcard.2006.05.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 2.  The efficacy of evolocumab in the management of hyperlipidemia: a systematic review.

Authors:  Lamia AlHajri; Asma AlHadhrami; Shama AlMheiri; Yalwah AlMutawa; Zainab AlHashimi
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-03-20

Review 3.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

4.  Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

Authors:  Justo Sierra-Johnson; Rachel M Fisher; Abel Romero-Corral; Virend K Somers; Francisco Lopez-Jimenez; John Ohrvik; Göran Walldius; Mai-Lis Hellenius; Anders Hamsten
Journal:  Eur Heart J       Date:  2008-08-01       Impact factor: 29.983

5.  Effect of increased leptin and C-reactive protein levels on mortality: results from the National Health and Nutrition Examination Survey.

Authors:  Stephen M Amrock; Michael Weitzman
Journal:  Atherosclerosis       Date:  2014-06-23       Impact factor: 5.162

6.  Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study.

Authors:  Eric Walter Pefura Yone; André Pascal Kengne; Gloria Ashuntantang; Awa Foueudjeu Betyoumin; Jeanne Ngogang
Journal:  BMJ Open       Date:  2012-08-08       Impact factor: 2.692

Review 7.  Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.

Authors:  Jesús Millán; Xavier Pintó; Anna Muñoz; Manuel Zúñiga; Joan Rubiés-Prat; Luis Felipe Pallardo; Luis Masana; Alipio Mangas; Antonio Hernández-Mijares; Pedro González-Santos; Juan F Ascaso; Juan Pedro-Botet
Journal:  Vasc Health Risk Manag       Date:  2009-09-18

8.  Lipoprotein ratios are better than conventional lipid parameters in predicting arterial stiffness in young men.

Authors:  Jianghua Wen; Yuyu Zhong; Chaoqun Kuang; Jierong Liao; Zhijin Chen; Qiong Yang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

9.  Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in Korean adults.

Authors:  Ji-Young Kim; Hee-Taik Kang; Hye-Ree Lee; Yong-Jae Lee; Jae-Yong Shim
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

10.  Both serum apolipoprotein B and the apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thickness.

Authors:  Fei Huang; Zhi Yang; Baihui Xu; Yufang Bi; Min Xu; Yu Xu; Jieli Lu; Yu Liu; Meng Dai; Wenzhong Zhou; Weiqing Wang; Yuhong Chen
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.